Completed PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT00499746

The Discriminative Effects of Tramadol in Humans

Medications Development for Drug Abuse Disorders

Sponsor: National Institute on Drug Abuse (NIDA)

Conditions Opioid Abuse Opioid Addiction Stimulant Abuse Stimulant Addiction

Interventions Hydromorphone Methylphenidate placebo tramadol

Updated 7 times since 2017 Last updated: Sep 14, 2017 Started: Nov 30, 2007 Primary completion: Apr 30, 2010 Completion: Aug 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Opioid Abuse and Opioid Addiction and is currently completed. National Institute on Drug Abuse (NIDA) leads this study, which shows 7 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Nov 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Nov 2017 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute on Drug Abuse (NIDA)

Data source: National Institute on Drug Abuse (NIDA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Baltimore, United States